Glycyrrhizin suppresses lung adenocarcinoma cell growth through inhibition of thromboxane synthase

Cellular Physiology and Biochemistry

Volumn 33, Issue 2, 2014, Pages 375-388

  Huang, Run Yue ^a   Chu, Yong Liang ^a   Jiang, Ze Bo ^b   Chen, Xiu Ming ^a   Zhang, Xian ^b   Zeng, Xing ^b  

^a Department of Rheumatology and ^*  (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Cell growth; Glycyrrhizin; Lung adenocarcinoma; Thromboxane synthase

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; GLYCYRRHIZIC ACID; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMALL INTERFERING RNA; SURVIVIN; THROMBOXANE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CYCLE ARREST; CELL GROWTH; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOSYNTHESIS; CANCER INHIBITION; CELL CYCLE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; MTS ASSAY;

ADENOCARCINOMA; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; GLYCYRRHIZIC ACID; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM PROTEINS; THROMBOXANE-A SYNTHASE;

EID: 84895652874     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000356677     Document Type: Article

References (47)

1. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba, II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-1075.
2. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene 2012;31:1869-1883.
3. Pompei R, Flore O, Marccialis MA, Pani A, Loddo B: Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature 1979;281:689-690.
4. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, Muhammad AK, Clark MC, Arditi M, Comin-Anduix B, Ribas A, Lowenstein PR, Castro MG: Hmgb1 mediates endogenous tlr2 activation and brain tumor regression. PLoS Med 2009;6:e10.
5. Shi L, Tang C, Yin C: Glycyrrhizin-modified o-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma. Biomaterials 2012;33:7594-7604.
6. Park SY, Lim SS, Kim JK, Kang IJ, Kim JS, Lee C, Kim J, Park JH: Hexane-ethanol extract of glycyrrhiza uralensis containing licoricidin inhibits the metastatic capacity of du145 human prostate cancer cells. Br J Nutr 2010;104:1272-1282.
7. Sampaio AL, Dalli J, Brancaleone V, D'Acquisto F, Perretti M, Wheatley C: Biphasic modulation of nos expression, protein and nitrite products by hydroxocobalamin underlies its protective effect in endotoxemic shock: Downstream regulation of cox-2, il-1beta, tnf-Alpha, il-6, and hmgb1 expression. Mediators Inflamm 2013;2013:741804.
8. Jaulmes A, Thierry S, Janvier B, Raymondjean M, Marechal V: Activation of spla2-iia and pge2 production by high mobility group protein b1 in vascular smooth muscle cells sensitized by il-1beta. FASEB J 2006;20:1727-1729.
9. Cavone L, Muzzi M, Mencucci R, Sparatore B, Pedrazzi M, Moroni F, Chiarugi A: 18beta-glycyrrhetic acid inhibits immune activation triggered by hmgb1, a pro-inflammatory protein found in the tear fluid during conjunctivitis and blepharitis. Ocul Immunol Inflamm 2011;19:180-185.
10. Smolarczyk R, Cichon T, Matuszczak S, Mitrus I, Lesiak M, Kobusinska M, Kamysz W, Jarosz M, Sieron A, Szala S: The role of glycyrrhizin, an inhibitor of hmgb1 protein, in anticancer therapy. Arch Immunol Ther Exp (Warsz) 2012;60:391-399.
11. Ni YF, Kuai JK, Lu ZF, Yang GD, Fu HY, Wang J, Tian F, Yan XL, Zhao YC, Wang YJ, Jiang T: Glycyrrhizin treatment is associated with attenuation of lipopolysaccharide-induced acute lung injury by inhibiting cyclooxygenase-2 and inducible nitric oxide synthase expression. J Surg Res 2011;165:e29-35.
12. Bhattacharjee S, Bhattacharjee A, Majumder S, Majumdar SB, Majumdar S: Glycyrrhizic acid suppresses cox-2-mediated anti-inflammatory responses during leishmania donovani infection. J Antimicrob Chemother 2012;67:1905-1914.
13. Edelman MJ, Hodgson L, Wang X, Kratzke RA, Vokes EE: Cyclooxygenase-2 (cox-2) as a predictive marker for the use of cox-2 inhibitors in advanced non-small-cell lung cancer. J Clin Oncol 2012;30:2019-2020; author reply 2020.
14. Huang RY, Chen GG: Cigarette smoking, cyclooxygenase-2 pathway and cancer. Biochim Biophys Acta 2011;1815:158-169.
15. Cathcart MC, Reynolds JV, O'Byrne KJ, Pidgeon GP: The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. Biochim Biophys Acta 2010;1805:153-166.
16. Ermert L, Dierkes C, Ermert M: Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 2003;9:1604-1610.
17. Pace E, Siena L, Ferraro M, Profita M, Mondello P, Chiappara G, Montalbano AM, Giarratano A, Bonsignore G, Gjomarkaj M: Role of prostaglandin e2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis. Eur J Cancer 2006;42:2382-2389.
18. Martey CA, Pollock SJ, Turner CK, O'Reilly KM, Baglole CJ, Phipps RP, Sime PJ: Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin e2 synthase in human lung fibroblasts: Implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol 2004;287:L981-991.
19. Harizi H, Corcuff JB, Gualde N: Arachidonic-Acid-derived eicosanoids: Roles in biology and immunopathology. Trends Mol Med 2008;14:461-469.
20. Ekambaram P, Lambiv W, Cazzolli R, Ashton AW, Honn KV: The thromboxane synthase and receptor signaling pathway in cancer: An emerging paradigm in cancer progression and metastasis. Cancer Metastasis Rev 2011;30:397-408.
21. Cathcart MC, Gately K, Cummins R, Kay E, O'Byrne KJ, Pidgeon GP: Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Mol Cancer 2011;10:25.
22. Leung KC, Li MY, Leung BC, Hsin MK, Mok TS, Underwood MJ, Chen GG: Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting nf-kappab. Exp Cell Res 2010;316:3468-3477.
23. Leung KC, Hsin MK, Chan JS, Yip JH, Li M, Leung BC, Mok TS, Warner TD, Underwood MJ, Chen GG: Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27. Exp Cell Res 2009;315:2974-2981.
24. Moussa O, Riker JM, Klein J, Fraig M, Halushka PV, Watson DK: Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. Oncogene 2008;27:55-62.
25. Li X, Tai HH: Increased expression of matrix metalloproteinases mediates thromboxane a2-induced invasion in lung cancer cells. Curr Cancer Drug Targets 2012;12:703-715.
26. Satomi Y, Nishino H, Shibata S: Glycyrrhetinic acid and related compounds induce g1 arrest and apoptosis in human hepatocellular carcinoma hepg2. Anticancer Res 2005;25:4043-4047.
27. Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: A systematic review and economic evaluation. Health Technol Assess 2013;17:1-278.
28. Huang L, Huang QY, Huang HQ: The evidence of hela cell apoptosis induced with tetraethylammonium using proteomics and various analytical methods. J Biol Chem 2014;289:2217-2229.
29. Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS, Doetsch PW: Cisplatin induces a mitochondrial-ros response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PloS One 2013;8:e81162.
30. Feinmark SJ, Bailey JM: Lipid metabolism in cultured cells. Activators of endogenous thromboxane a2 synthesis in cultured lung fibroblasts. J Biol Chem 1982;257:2816-2821.
31. Kohyama T, Liu X, Wen FQ, Kim HJ, Takizawa H, Rennard SI: Potentiation of human lung fibroblast chemotaxis by the thromboxane a(2) analog u-46619. J Lab Clin Med 2002;139:43-49.
32. Tesar PJ, Chenoweth JG, Brook FA, Davies TJ, Evans EP, Mack DL, Gardner RL, McKay RD: New cell lines from mouse epiblast share defining features with human embryonic stem cells. Nature 2007;448:196-199.
33. Brons IG, Smithers LE, Trotter MW, Rugg-Gunn P, Sun B, Chuva de Sousa Lopes SM, Howlett SK, Clarkson A, Ahrlund-Richter L, Pedersen RA, Vallier L: Derivation of pluripotent epiblast stem cells from mammalian embryos. Nature 2007;448:191-195.
34. Wu YC, Su LJ, Wang HW, Jeff Lin CF, Hsu WH, Chou TY, Huang CY, Lu CL, Hsueh CT: Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin e synthase-1 adversely affects the postoperative survival in non-small cell lung cancer. J Thorac Oncol 2010;5:1167-1174.
35. Huang R-Y, Li M-Y, Ng CS, Wan IY, Kong AW, Du J, Long X, Underwood MJ, Mok TS, Chen GG: Thromboxane a2 receptor α promotes tumor growth through an autoregulatory feedback pathway. J Mol Cell Biol 2013;5:380-390.
36. Huang RY, Li MY, Hsin MK, Underwood MJ, Ma LT, Mok TS, Warner TD, Chen GG: 4-methylnitrosamino-1-3-pyridyl-1-butanone (nnk) promotes lung cancer cell survival by stimulating thromboxane a2 and its receptor. Oncogene 2011;30:106-116.
37. Sakai H, Suzuki T, Takahashi Y, Ukai M, Tauchi K, Fujii T, Horikawa N, Minamimura T, Tabuchi Y, Morii M, Tsukada K, Takeguchi N: Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane a2. FEBS Lett 2006;580:3368-3374.
38. Moussa O, Yordy JS, Abol-Enein H, Sinha D, Bissada NK, Halushka PV, Ghoneim MA, Watson DK: Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. Cancer Res 2005;65:11581-11587.
39. Watkins G, Douglas-Jones A, Mansel RE, Jiang WG: Expression of thromboxane synthase, tbxas1 and the thromboxane a2 receptor, tbxa2r, in human breast cancer. Int Semin Surg Oncol 2005;2:23.
40. Marshall K, Lane K, Senior J: Growth inhibitory effects of thromboxane antagonists on breast cancer cell lines: A preliminary study. Adv Exp Med Biol 1997;400A:455-460.
41. Nigam S, Zakrzewicz A, Eskafi S, Roscher A: Clinical significance of prostacyclin and thromboxane in cancer of the female breast and genital tract. Cancer Metastasis Rev 1992;11:411-420.
42. Aitokallio-Tallberg A, Karkkainen J, Pantzar P, Wahlstrom T, Ylikorkala O: Prostacyclin and thromboxane in breast cancer: Relationship between steroid receptor status and medroxyprogesterone acetate. Br J Cancer 1985;51:671-674.
43. Ylikorkala O, Kauppila A, Viinikka L: Prostacyclin and thromboxane in ovarian cancer: Effect of cytostatics and prostaglandin synthesis inhibitors. Gynecol Oncol 1983;16:340-345.
44. Horrobin DF, Karmali RA, Manku MS, Ally AI, Morgan RO, Cunnane SC, Karmazyn M: A defect in thromboxane a2 synthesis may be a factor predisposing to cancer. Prostaglandins Med 1978;1:175-181.
45. Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn A, Herbst RS, Li C, Lee HY: Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-Type plasminogen activator inhibition. Mol Cancer Ther 2006;5:2685-2695.
46. Wei J, Yan W, Li X, Ding Y, Tai HH: Thromboxane receptor alpha mediates tumor growth and angiogenesis via induction of vascular endothelial growth factor expression in human lung cancer cells. Lung Cancer 2010;69:26-32.
47. Moussa O, Ashton AW, Fraig M, Garrett-Mayer E, Ghoneim MA, Halushka PV, Watson DK: Novel role of thromboxane receptors beta isoform in bladder cancer pathogenesis. Cancer Res 2008;68:4097-4104.